Enorama Pharma AB (publ) Explores Divestment of Nicotine Replacement Therapy Chewing Gum Business
The board of directors at Enorama Pharma AB (“Enorama Pharma” or the “Company”) has decided to explore the possibility of divesting the part of the business developing and selling its nicotine replacement therapy (“NRT”) chewing gum, to focus on the continued expansion of its NIC-S nicotine pouch product line.
Enorama Pharma has developed a patented range of NRT chewing gums in two strengths and two flavors, featuring superior gum characteristics. The product is already registered in seven European countries. Former CEO Annette Agerskov will lead the divestment process.
“I look forward to leading this process and believe the NRT business holds great value. We will carefully explore all options to ensure the best possible outcome for Enorama.” says Annette Agerskov.
“It makes good sense for Enorama to evaluate a divestment of the NRT gum business. The NRT market is highly attractive to many international companies with established pharma operations. If the financial terms of the divestment are favorable, we plan to concentrate fully on expanding our pouch business, including markets outside the U.S.” says Daniel Schröder, CEO of Enorama.
CONTACT
Enorama Pharma AB (publ)
Daniel Schröder, VD
Södra Förstadsgatan 1, 211 43 Malmö
www.enorama.se
Enorama Pharma AB is listed on Nasdaq First North Growth Market.
The Company’s Certified Adviser is Carnegie Investment Bank AB (publ): +46 (0)73 856 42 65, [email protected].
ABOUT ENORAMA PHARMA
Enorama Pharma's goal is to become a leading global supplier of consumer-friendly nicotine replacement products. The business concept is to develop and sell both medical chewing gum and non-medical, tobacco-free nicotine products and offer these both as Private Label and under own brands. For more information, visit www.enorama.se.
This information is information that Enorama Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-09-25 12:00 CEST.
